Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
Launched by CENTRO OFTALMOLÓGICO DR CHARLES · Jul 25, 2020
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
This is the retrospective study of 14 consecutive patients suffering from retinal detachment with proliferative vitreoretinopathy who underwent primary PPV at the Department of Retina of Centro Oftalmologico Dr Charles, Buenos Aires-Argentina between January 1, 2016 and August 1, 2020 . This study followed the tenets of the Declaration of Helsinki and it was approved by the approved by the research ethics committee (www.comitedeeticaceic.com.ar). Written informed consent was taken from all subjects. All cases were performed by a single experienced vitreoretinal surgeon (MCH)
The treatment ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients older than 18 years age suffering from retinal detachment with proliferative vitreoretinopathy who underwent primary PPV at the Department of Retina of Centro Oftalmologico Dr Charles, Buenos Aires-Argentina between January 1, 2016 and August 1, 2020 .
- Exclusion Criteria:
- • patients younger than 18 years age
About Centro Oftalmológico Dr Charles
Centro Oftalmológico Dr. Charles is a leading clinical research organization dedicated to advancing ophthalmic care through innovative clinical trials. Renowned for its commitment to excellence, the center specializes in a wide range of ocular conditions and collaborates with industry partners to explore cutting-edge treatments and therapies. With a team of experienced ophthalmologists and researchers, Centro Oftalmológico Dr. Charles is dedicated to improving patient outcomes and contributing to the global body of knowledge in eye health. Their state-of-the-art facilities and patient-centric approach ensure a rigorous and ethical research environment, fostering advancements in vision care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buenos Aires, Capital Federal, Argentina
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials